The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVERS.L Regulatory News (VERS)

  • There is currently no data for VERS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

21 Nov 2019 16:40

RNS Number : 2782U
Verseon Corporation
21 November 2019
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APMDMMZMVMGGLZM
Date   Source Headline
24th Oct 20187:00 amRNSAnnouncement of 2018 Annual General Meeting
11th Oct 20187:00 amRNSBlockchain agreement with Neuseren
1st Oct 20188:59 amRNSAdditional Listing & Total Voting Rights
18th Sep 20187:00 amRNSVerseon unveils new blockchain technology
13th Sep 20187:00 amRNSVerseon commences anticoagulant phase I trial
31st Aug 20187:00 amRNSAdditional Listing & Total Voting Rights
16th Aug 20187:00 amRNSChange of Adviser
8th Aug 20187:00 amRNSInterim Results
18th Jul 20187:00 amRNSVerseon submits phase I protocol for VE-1902
6th Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
2nd Jul 20187:00 amRNSAdditional Listing & Total Voting Rights
25th Jun 20187:00 amRNSFinal Results
14th Jun 20187:00 amRNSVerseon preparing for anticoagulant phase I trial
13th Jun 20187:03 amRNSVerseon closes US$ 22.7M mortgage
12th Jun 20187:00 amRNSAdditional Listing & Total Voting Rights
7th Jun 20187:00 amRNSVerseon presents anticoagulants at BIO 2018
2nd May 20187:00 amRNSVerseon presents DME efficacy data at ARVO 2018
18th Apr 20187:00 amRNSVerseon presents anticancer agents at AACR 2018
3rd Apr 20187:00 amRNSAdditional Listing & Total Voting Rights
5th Mar 20187:00 amRNSAdditional Listing & Total Voting Rights
10th Jan 20187:00 amRNSVerseon presents HAE program at Biotech Showcase
2nd Jan 20187:00 amRNSAdditional Listing & Total Voting Rights
15th Nov 20177:00 amRNSVerseon presents second anticoagulant candidate
14th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
8th Nov 20177:00 amRNSVerseon presents anticancer agents at BIO-Europe
8th Nov 20177:00 amRNSAdditional Listing & Total Voting Rights
20th Oct 20177:00 amRNSResult of Special Meeting & Board Appointment
2nd Oct 20177:00 amRNSVerseon presents new DME efficacy results
25th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSSpecial Shareholder Meeting & Change of Directors
22nd Sep 20177:00 amRNSVerseon closes PACE financing for its new facility
7th Aug 20177:00 amRNSAdditional Listing and Total Voting Rights
26th Jun 20177:00 amRNSVerseon presents data on DME program at BIO 2017
12th Jun 20177:00 amRNSVerseon to present drug programs at BIO 2017
6th Jun 20178:15 amRNSTransaction in Own Shares and Total Voting Rights
2nd May 20177:00 amRNSAdditional Listing & Total Voting Rights
26th Apr 20177:00 amRNSTR-1 Notification of Major Interest in Shares
26th Apr 20177:00 amRNSResult of 2017 Annual General Meeting
3rd Apr 20177:00 amRNSAnnouncement of 2017 Annual General Meeting
30th Mar 20177:00 amRNSVerseon to present anticoagulants at ACS 2017
20th Mar 20177:00 amRNSBIO-Europe Spring: Verseon presents anticoagulants
13th Mar 20177:00 amRNSFinal Results
30th Jan 20177:00 amRNSAdditional Listing & Total Voting Rights
4th Jan 20177:00 amRNSVerseon granted US patents for its inhibitors
6th Dec 20167:00 amRNSLower bleeding risk of Verseon anticoagulants
23rd Nov 20167:03 amRNSVerseon anticoagulants preserve platelet function
16th Nov 20167:00 amRNSAdditional Listing & Total Voting Rights
14th Nov 20167:00 amRNSNew anticoagulant data to be presented at AHA 2016
7th Nov 20167:00 amRNSAppointment of Corporate Brokers
31st Oct 20167:00 amRNSAdditional Listing & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.